Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market

For years, Roche’s blockbuster oncology troika—Rituxan, Herceptin and Avastin—dominated sales stateside and abroad. For two drugs in that superstar trio, those landmark years could be approaching an end.